Ranok Therapeutics (Hangzhou) Co., Ltd.
Ranok Therapeutics (Hangzhou) Co., Ltd.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects | Food Effect; Mass Balance | Not yet recruiting | Phase 1 | 2026-01-14 | NCT07334262 | |
| To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. | KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 2 | 2025-12-24 | NCT07303465 | |
| A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation | KRAS G12D Mutation | Recruiting | Phase 1 / Phase 2 | 2025-10-30 | NCT06667544 | |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | diffuse large B-cell lymphoma | Recruiting | Phase 1 / Phase 2 | 2025-03-04 | NCT05487170 |